Elizabeth Plimack, MD, Director of Genitourinary Clinical Research, Associate Professor, department of hematology/oncology, Fox Chase Cancer Center, discusses which patients should receive nivolumab and how it and other novel agents should be sequenced in renal cell carcinoma (RCC).
Most RCC patients should receive nivolumab, said Plimack. Very few patients are ineligible, however those with autoimmune diseases, even if it is well-controlled, should not receive the drug.
Patients are living longer with RCC and therefore most will receive multiple novel agents, including nivolumab and cabozantinib, at some point during the duration of their treatment. The question of when each patient should receive which drug is still being determined, said Plimack.